Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus

Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus

ObjectiveBaricitinib, a selective inhibitor for janus kinase (JAK) 1 and JAK2, is approved for use in rheumatoid arthritis. Systemic lupus erythematosus (SLE) is recently regarded as a potential candidate targeted by JAK inhibitors because of the relationship between its pathogenesis and JAK/signal...

Full description

Bibliographic Details
Main Authors: Jaeseon Lee, Youngjae Park, Se Gwang Jang, Seung-Min Hong, Young-Seok Song, Min-Jun Kim, SeungYe Baek, Sung-Hwan Park, Seung-Ki Kwok
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Immunology
Subjects:
systemic lupus erythematosus
baricitinib
renal inflammation
podocyte
B cell
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.704526/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.704526/full

Similar Items